Skip to main content

Table 1 Polysomnograph results in a patient with Prader-Willi syndrome and narcoleptic and cataplectic symptoms 1

From: Prader-Willi syndrome, excessive daytime sleepiness, and narcoleptic symptoms: a case report

  2y 10mo 5y 3mo 6y 10mo 8y 5mo 9y 3mo
Sleep architecture
Total sleep time (min) 420.5 489.5 516.5 520 492
Sleep efficiency (%) 84.9 90.8 92.7 94.4 95.1
Sleep stages total sleep time
Stage 1 (%) 6.5 2.2 2.5 0.6 2.1
Stage 2 (%) 43.4 48.1 57.9 64.7 59.3
Stage 3 and 4 (%) 22.5 25.8 18.6 18 18.5
REM (%) 27.6 23.9 21.0 16.8 20.1
Apnea events
Central apnea index (events per hour) 0.57 0 0.46 2.08 2.32
Obstructive apnea index (events per hour) 0.14 0.12 0 0.12 0
Number of mixed events per hour 0.43 0 0.58 0 0
Hypopnea events (events per hour) 0.29 0.25 0.23 0.34 3.05
Apnea-hypopnea index (events per hour) 1.4 0.4 1.3 2.7 5.6
End-tidal carbon dioxide (ETCO2)
Mean total recorded ETCO2 (mmHg) 44.5 46 42 43 45
Maximum total recorded ETCO2 (mmHg) 60.9 60 51 50 54
Oxygen saturation (SaO2)
Mean total recorded SaO2 (%) 94.1 95 97 94 96
Minimum total recorded SaO2 (%) 78.7 87 88 84 84
Anthropometrics
Height (cm) 84 97 104 110 116
Weight (kg) 11.25 15.2 17.4 20.0 21.4
BMI- z score 0.12 0.66 0.39 0.25 −0.23
  1. 1Modafinil therapy was initiated at age seven years six months; growth hormone therapy was initiated at age eight years eight months. REM, rapid eye movement; BMI body mass index.
\